Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update.
马萨诸塞州剑桥--（美国商业资讯）-- 锡罗斯制药 致力于推进血液系统恶性肿瘤一线治疗新护理标准的生物制药公司纳斯达克股票代码：SYRS）今天宣布，它将在美国东部时间2024年5月14日星期二上午 8:30 举办电话会议和网络直播，以报告其2024年第一季度财务业绩并提供公司最新情况。
To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 16518. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the call.
要观看电话会议，请拨打 (800) 549-8228（国内）或 (289) 819-1520（国际），并参考会议编号16518。电话会议的网络直播也将在Syros网站的 “投资者与媒体” 栏目上播出 www.syros.com。电话会议结束后的大约30天内将提供网络直播的存档重播。
About Syros Pharmaceuticals
关于锡罗斯制药
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
Syros致力于为血液恶性肿瘤患者的一线治疗制定新的护理标准。出于帮助基本上无法获得其他靶向治疗的血液疾病患者的动机，Syros正在开发tamibarotene，这是一种口服选择性 RARα激动剂，用于患有高危骨髓增生异常综合征和急性髓系白血病的一线患者 RARA 基因过度表达。欲了解更多信息，请访问 www.syros.com 然后在推特上关注我们 (@SyrosPharma) 和 领英。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507911048/en/
在 businesswire.com 上查看源版本： https://www.businesswire.com/news/home/20240507911048/en/
Syros Contact
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Syros 联系人
凯伦汉迪
企业传播与投资者关系总监
1-857-327-7321
khunady@syros.com
投资者联系人
汉娜·德雷西维奇
斯特恩投资者关系有限公司
212-362-1200
hannah.deresiewicz@sternir.com
Source: Syros Pharmaceuticals
来源：锡罗斯制药
Released May 7, 2024
2024 年 5 月 7 日发布